Last updated: April 25, 2026
Who Supplies Doxercalciferol (Drug Substance & Key Starting Materials) and Where Are the Supply Risks?
Doxercalciferol is also known as 22-oxa-1α,25-(OH)2-vitamin D3 (often marketed as a vitamin D analog). Supply for this molecule and its downstream dosage forms typically concentrates in two layers: (1) API manufacturers that supply doxercalciferol (drug substance) and (2) ingredient and intermediate suppliers that support commercial synthesis routes.
Because “doxercalciferol” is a specialty vitamin D analog with a narrow market, the supplier landscape tends to be small and stable, with long lead times and tightly controlled quality systems.
Which suppliers actually make doxercalciferol as an API?
The supplier set for doxercalciferol is not broad; it is usually concentrated among firms that sell regulated vitamin D analog APIs and related intermediates under GMP. In practice, buyers obtain doxercalciferol through:
- API manufacturers of vitamin D analogs (direct API supply)
- Contract manufacturing organizations (CMOs) that qualify doxercalciferol routes and can scale under GMP
- Specialty distributors that source the API from one of the limited upstream GMP producers and sell under their own distribution licenses
At the record level, the most decision-relevant data for “who supplies doxercalciferol” comes from regulatory and compendial listings tied to marketed products (who holds the drug application and who is named for manufacturing/packaging), plus API catalog or DMF-based supplier qualification data. For doxercalciferol specifically, the supplier list depends on the dosage form and jurisdiction because different markets source from different qualified API suppliers even when the drug substance name is identical.
What supplier types should procurement teams map first?
Procurement teams that need supply assurance typically map the ecosystem in this order:
| Priority layer |
What to map |
Why it matters for supply continuity |
| 1 |
GMP API maker(s) of doxercalciferol |
Direct control of batch release, lead time, and technical transfer feasibility |
| 2 |
Validated intermediate suppliers used in doxercalciferol synthesis |
Intermediate availability often controls the API schedule more than raw materials |
| 3 |
Finish-and-pack suppliers (if buying finished product rather than API) |
Packaging capacity and labeling constraints drive drug supply risk |
| 4 |
Quality and analytics providers supporting stability and release testing |
Vitamin D analogs require strict analytical capability for potency and impurity control |
What are the actual supply risk points in doxercalciferol?
Doxercalciferol is a secosteroid analog; supply risk is typically driven by:
- Limited number of qualified GMP producers
- Tight controls on vitamin D analog manufacturing (light/oxidation sensitivity in handling and processing)
- Intermediate bottlenecks on steroid-core chemistry
- Analytical method dependence (potency and impurity profiling)
Where does supply bottleneck typically occur?
The most common chokepoints for vitamin D analog supply programs are:
- Steroid-core construction steps using specialized chemistry
- Key photo-sensitive transformations
- Intermediate purification and solvent handling constraints
- Analytical release testing capacity (HPLC/UPLC methods, impurity profiling)
How do drug approvals indicate likely API and manufacturing suppliers?
For vitamin D analogs, procurement and diligence workflows often use regulatory filings to identify:
- Manufacturing sites for the drug product (packaging, release testing)
- Manufacturing and control site information that sometimes overlaps with API sites
- Cross-references to DMFs for the API, where applicable
Even when the label does not state the API manufacturer, recurring site names across multiple filings in a country can identify which GMP network is supplying the market.
Supplier shortlist framework (actionable procurement mapping)
Even without a broad catalog-style list, procurement can build an actionable shortlist using a repeatable approach that reliably narrows to the few credible suppliers for doxercalciferol.
Step 1: Identify the market-facing product manufacturers
Map the firms that manufacture and distribute doxercalciferol products by jurisdiction. Then:
- Identify the manufacturing/packaging site names from regulatory product records.
- Check whether those sites also perform API control or hold an API manufacturing capability.
Step 2: Extract candidate API source names from dossiers
For each candidate, look for:
- DMF references or supplier-of-record names tied to impurity specifications and method validation
- Repeated supplier names across product portfolios
Step 3: Qualify alternates through technical transfer readiness
For vitamin D analogs, qualification is constrained by:
- Stability program design
- Method suitability for potency and impurities
- Process understanding for light/oxidation sensitive intermediates
Key technical requirements procurement teams use to lock supply
When requesting doxercalciferol API quotes, procurement typically focuses on these hard specs.
What quality and analytical controls are typical for doxercalciferol API?
| Category |
What procurement confirms |
Practical reason |
| Identity |
Spectral identity (commonly HPLC/UV and MS where relevant) |
Prevents isomer and degradation substitutions |
| Assay (potency) |
Verified potency vs reference standard |
Vitamin D analogs require exact potency alignment |
| Impurities |
Controlled impurity panel with limits |
Secosteroid synthesis generates specific byproducts |
| Solvents |
Residual solvent compliance |
Steroid chemistry uses specialized solvents |
| Stability |
Defined storage conditions and re-test interval |
Light and oxidation sensitivity impacts shelf life |
Where do API distributors fit in?
In most markets, the distributor layer matters when:
- the API maker sells primarily through qualified channels
- small customers need faster access without full qualification cycles
- language and logistics become a gating factor
Distributors generally improve commercial access but do not remove technical qualification constraints for the end customer.
Key Takeaways
- Doxercalciferol supply is concentrated in a small number of GMP-capable API producers and a distributor/CMO layer that depends on those upstream sources.
- The most material supply risks usually arise from intermediate bottlenecks and analytical release capacity rather than general bulk chemical availability.
- The most reliable way to identify “who supplies doxercalciferol” is to triangulate from jurisdictional product manufacturing records and dossier/DMF supplier references, then map those names to GMP sites that can support technical transfer.
FAQs
-
Is doxercalciferol sourced by many different API manufacturers?
No. The supply chain for vitamin D analogs typically concentrates in a small number of specialized GMP networks.
-
Do product manufacturers always make the doxercalciferol API they sell?
Not necessarily. Drug product manufacturing sites can differ from API production sites; many products rely on external GMP API suppliers.
-
What causes the longest lead times for doxercalciferol?
Commonly, intermediate availability and the light-sensitive, tightly controlled synthesis and purification steps that impact schedule execution.
-
What qualification evidence matters most when switching doxercalciferol suppliers?
Assay/potency alignment, impurity profile comparability, validated analytical method suitability, and stability data under proposed storage conditions.
-
Should procurement start with API makers or finish-and-pack suppliers?
Start with GMP API makers (and their intermediate network) if you are buying API. Start with finish-and-pack suppliers if you are buying finished product.
References
[1] United States Food and Drug Administration (FDA). Drug Approval Packages (where applicable) and labeling/manufacturing information for relevant doxercalciferol-containing products. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). European public assessment reports and product information for doxercalciferol-containing medicines where applicable. EMA. https://www.ema.europa.eu/
[3] U.S. National Library of Medicine. Drug label and substance references used to identify doxercalciferol aliases and regulatory contexts. PubChem/MedlinePlus. https://pubchem.ncbi.nlm.nih.gov/
